Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma

Authors

  • Oktay Unsal Gazi University, Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye
  • Ozan Yazici Gazi University, Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye
  • Nuriye Ozdemir Gazi University, Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye
  • Ahmet Ozet Gazi University, Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye

Keywords:

Nivolumab, Elderly patients, Malign melanoma, Anti pd-1

Abstract

Aim:  This study aimed to analyse the clinical characteristics, effectiveness and safety of nivolumab monotherapy in patients aged≥ 65 years with metastatic melanoma.

Materials and Methods: This study involved patients aged ≥65 years who were diagnosed with metastatic cutaneous or mucosal melanoma. Patients with BRAF wild type, ECOG performance status 0-1, and who had previously received one line of chemotherapy were included, irrespective of PD-L1 expression. The study analyzed PFS, OS, and adverse event profiles.

Results: Twenty-one patients, with a median age of 70, were analysed in the study. The median PFS for nivolumab as second-line therapy in elderly patients was 3.5 months (95% CI, 1.5 to 5.6 months), while the median OS was 14.5 months (95% CI, 10.3 to 18.6 months). The most common grade 1-2 adverse events were anemia (66.7%) and serum creatinine increase (23.8%). Additionally, the rate of grade 3-4 adverse events due to all causes was 28.6%. There was no grade 5 adverse event.

Conclusion: Nivolumab is effective and safe as second-line therapy in patients aged ≥65 years with metastatic melanoma. It is a tolerable and effective treatment choice for elderly patients who cannot received nivolumab in first line therapy.

Downloads

Download data is not yet available.

Downloads

Published

2023-08-25

Issue

Section

Original Articles

How to Cite

1.
Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Ann Med Res [Internet]. 2023 Aug. 25 [cited 2025 Apr. 3];30(8):965-9. Available from: http://annalsmedres.org/index.php/aomr/article/view/4502